JP7769695B2 - Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用 - Google Patents

Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用

Info

Publication number
JP7769695B2
JP7769695B2 JP2023523059A JP2023523059A JP7769695B2 JP 7769695 B2 JP7769695 B2 JP 7769695B2 JP 2023523059 A JP2023523059 A JP 2023523059A JP 2023523059 A JP2023523059 A JP 2023523059A JP 7769695 B2 JP7769695 B2 JP 7769695B2
Authority
JP
Japan
Prior art keywords
disease
crystal
compound
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023523059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546125A5 (https=
JP2023546125A (ja
JPWO2022078352A5 (https=
Inventor
チョン，ウェンジ
グオ，ウェイ
リー，チェン・ジェーン
ジアン，シャーウェイ
チェン，ペンギュアン
Original Assignee
キル・レガー・セラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キル・レガー・セラピューティクス・インコーポレーテッド filed Critical キル・レガー・セラピューティクス・インコーポレーテッド
Publication of JP2023546125A publication Critical patent/JP2023546125A/ja
Publication of JP2023546125A5 publication Critical patent/JP2023546125A5/ja
Publication of JPWO2022078352A5 publication Critical patent/JPWO2022078352A5/ja
Application granted granted Critical
Publication of JP7769695B2 publication Critical patent/JP7769695B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2023523059A 2020-10-14 2021-10-13 Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用 Active JP7769695B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120814 2020-10-14
CNPCT/CN2020/120814 2020-10-14
PCT/CN2021/123387 WO2022078352A1 (en) 2020-10-14 2021-10-13 Crystal forms of glp-1r agonists and uses thereof

Publications (4)

Publication Number Publication Date
JP2023546125A JP2023546125A (ja) 2023-11-01
JP2023546125A5 JP2023546125A5 (https=) 2024-10-21
JPWO2022078352A5 JPWO2022078352A5 (https=) 2024-10-21
JP7769695B2 true JP7769695B2 (ja) 2025-11-13

Family

ID=78401981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523059A Active JP7769695B2 (ja) 2020-10-14 2021-10-13 Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用

Country Status (9)

Country Link
US (1) US12516041B2 (https=)
EP (1) EP4228753B1 (https=)
JP (1) JP7769695B2 (https=)
CN (1) CN116710446B (https=)
AU (1) AU2021359493A1 (https=)
CA (1) CA3195264A1 (https=)
ES (1) ES3041328T3 (https=)
TW (1) TWI912388B (https=)
WO (1) WO2022078352A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210069000A (ko) * 2019-12-02 2021-06-10 현대약품 주식회사 Glp-1 수용체 작용제
KR20240068737A (ko) 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
CN117362282B (zh) * 2022-07-07 2026-04-21 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用
AU2023310481A1 (en) * 2022-07-18 2025-03-06 Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd Polymorphic form of glp-1r agonist, preparation method therefor and use thereof
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513431A (ja) 2008-03-07 2011-04-28 トランス テック ファーマ，インコーポレイテッド 糖尿病の治療のためのオキサジアゾアントラセン化合物
US20180170908A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. GLP-1 Agonists and Uses Thereof
JP2021528394A (ja) 2018-06-15 2021-10-21 ファイザー・インク Ｇｌｐ−１受容体アゴニストおよびその使用
JP2022508203A (ja) 2018-11-22 2022-01-19 キル・レガー・セラピューティクス・インコーポレーテッド Ｇｌｐ－１ｒアゴニスト及びその使用
JP2022527607A (ja) 2019-04-12 2022-06-02 キル・レガー・セラピューティクス・インコーポレーテッド Ｇｌｐ－１ｒアゴニスト及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US10954221B2 (en) * 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513431A (ja) 2008-03-07 2011-04-28 トランス テック ファーマ，インコーポレイテッド 糖尿病の治療のためのオキサジアゾアントラセン化合物
US20180170908A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. GLP-1 Agonists and Uses Thereof
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
JP2021528394A (ja) 2018-06-15 2021-10-21 ファイザー・インク Ｇｌｐ−１受容体アゴニストおよびその使用
JP2022508203A (ja) 2018-11-22 2022-01-19 キル・レガー・セラピューティクス・インコーポレーテッド Ｇｌｐ－１ｒアゴニスト及びその使用
JP2022527607A (ja) 2019-04-12 2022-06-02 キル・レガー・セラピューティクス・インコーポレーテッド Ｇｌｐ－１ｒアゴニスト及びその使用

Also Published As

Publication number Publication date
EP4228753C0 (en) 2025-07-30
JP2023546125A (ja) 2023-11-01
ES3041328T3 (en) 2025-11-11
EP4228753B1 (en) 2025-07-30
US12516041B2 (en) 2026-01-06
WO2022078352A1 (en) 2022-04-21
CA3195264A1 (en) 2022-04-21
AU2021359493A9 (en) 2025-01-09
US20230382899A1 (en) 2023-11-30
CN116710446A (zh) 2023-09-05
TWI912388B (zh) 2026-01-21
CN116710446B (zh) 2024-10-18
AU2021359493A1 (en) 2023-06-15
TW202227421A (zh) 2022-07-16
EP4228753A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
JP7702973B2 (ja) Ｇｌｐ－１ｒアゴニストの塩及び結晶形態、並びにそれらの使用
JP7769695B2 (ja) Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用
TWI839416B (zh) Ｇｌｐ-１ｒ促效劑及其用途
TWI809334B (zh) ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
TW202214622A (zh) Ｇｌｐ－１ｒ促效劑及其用途
JP6637641B1 (ja) Ｇｌｐ−１受容体アゴニストおよびその使用
EP4537816A2 (en) Treatment of type-2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof
EP4482577A1 (en) Compounds as glp-1r agonists
HK40089377A (en) Crystal forms of glp-1r agonists and uses thereof
HK40089377B (en) Crystal forms of glp-1r agonists and uses thereof
HK40087545A (en) Salt and crystal forms of glp-1r agonists and uses thereof
HK40087545B (en) Salt and crystal forms of glp-1r agonists and uses thereof
TWI913272B (zh) Ｇｌｐ-１ｒ促效劑之鹽和晶型及其用途
CN104926706B (zh) 六氢并环戊二烯衍生物的盐及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251031

R150 Certificate of patent or registration of utility model

Ref document number: 7769695

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150